Novo Nordisk CEO on Pricing, U.S. Investments, M&A

The transcript covers a discussion on the company's pricing outlook for 2017, insights from a meeting with President Trump regarding regulatory changes, potential impacts of H1B visa changes, and the company's strategic focus on growth areas like diabetes and obesity. It also addresses share price performance and investor expectations.

What opportunities does the speaker see in the obesity market?

What are the unmet medical needs in the diabetes space according to the speaker?

What is the speaker's outlook on the share price performance and investor expectations?